Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    Phase 2 Begins in XC001 Trial for Refractory Angina
    source: pixabay.com

    Phase 2 Begins in XC001 Trial for Refractory Angina

      Previously, biopharmaceutical company XyloCor Therapeutics ("XyloCor") performed the first portion (dose-escalation) of the Phase 1/2 EXACT clinical trial evaluating its investigational treatment XC001 (encoberminogene rezmadenovec) for patients with refractory…

    Continue Reading Phase 2 Begins in XC001 Trial for Refractory Angina
    DAY101 for pLGG Granted Rare Pediatric Disease Status
    source: pixabay.com

    DAY101 for pLGG Granted Rare Pediatric Disease Status

    According to a July 27 news release from biopharmaceutical company Day One Biopharmaceuticals ("Day One"), the company's therapeutic option DAY101 received Rare Pediatric Disease designation within the United States. Altogether,…

    Continue Reading DAY101 for pLGG Granted Rare Pediatric Disease Status
    Venclexta with Azacitidine Granted Breakthrough Therapy Designation for MDS
    https://unsplash.com/photos/_jbClosDsD4

    Venclexta with Azacitidine Granted Breakthrough Therapy Designation for MDS

    In a news release from July 21, 2021, biotechnology company Genentech shared that its therapy Venclexta (venetoclax), in conjunction with azacitidine, received Breakthrough Therapy designation from the FDA. Overall, the…

    Continue Reading Venclexta with Azacitidine Granted Breakthrough Therapy Designation for MDS
    Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation
    source: pixabay.com

    Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation

    Medical studies are crucial players in the journey to develop new and more efficacious treatment options for patients with rare diseases. On June 10, 2021, Vertex Pharmaceuticals Incorporated ("Vertex") shared…

    Continue Reading Promising Data from Phase 2 VX-864 Study for A1AD, Despite Discontinuation